Drug research

Retifanlimab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as INCMGA00012; MGA012; Zynyz

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825	MacroGenics	Phase 2	Terminated	2022-07-29Actual
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364	MacroGenics	Phase 2, Phase 3	Completed	2024-01-15Actual
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612	BriaCell Therapeutics Corporation	Phase 3	Recruiting	2027-12Estimated

MacroGenicsTerminatedPrimary completion: 2022-07-29 · Actual

Trial details

MacroGenicsCompletedPrimary completion: 2024-01-15 · Actual

Trial details

BriaCell Therapeutics CorporationRecruitingPrimary completion: 2027-12 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.